Diabetes mellitus is going to affect the health of millions if it is allowed to continue to raise in the present manner and we are aware of this noncommunicable disease epidemic. There are some measures to delay the onset or prevent the diabetes mellitus. It is going to be essential to findout why these measures are not adequately implemented in the countries. There studies to find out the reasons for the indequate preventive measure implementation.
The Diabetes Prevention Program (DPP) clinical trial and its 10-year outcomes study (DPPOS), both sponsored by the National Institutes of Health (NIH), showed that certain interventions could prevent or substantially delay the onset of type 2 diabetes both safely and cost-effectively. Yet diabetes prevention is not widely practiced in the United States, and the disease's staggering human and financial costs continue to grow. It is therefore essential to identify the factors impeding the full realization of the DPP interventions' potential for preventing diabetes.
In DPP trial (3234) overweight or obese adults with IGT (prediabetes) were assigned to receive one of three interventions: lifestyle intervention aimed at modest weight loss through diet and exercise, treatment with generic metformin, or a placebo control. DPP findings published in 2002 indicated that, relative to placebo, lifestyle intervention and metformin reduced the rate of conversion to diabetes by 58% and 31%, respectively, over 3 years.1
Metformin worked well in younger women with history of gestational diabetes. Exercise and life style modifications worked well in people ( both genders) above 60 years of age.
Most DPP participants (88%) enrolled in the DPPOS ( 10 year study) , in which continued follow-up demonstrated that the 10-year risk reduction for type 2 diabetes was 31% for lifestyle intervention and 18% for metformin.2
We need to wait and see in India for the effectiveness of life style modifications in the rural and urban populations in preventing IGT conversion to diabetes mellitus, this can avert major risks associated with the potential epidemic of diabetes in the coming years.
The Diabetes Prevention Program (DPP) clinical trial and its 10-year outcomes study (DPPOS), both sponsored by the National Institutes of Health (NIH), showed that certain interventions could prevent or substantially delay the onset of type 2 diabetes both safely and cost-effectively. Yet diabetes prevention is not widely practiced in the United States, and the disease's staggering human and financial costs continue to grow. It is therefore essential to identify the factors impeding the full realization of the DPP interventions' potential for preventing diabetes.
In DPP trial (3234) overweight or obese adults with IGT (prediabetes) were assigned to receive one of three interventions: lifestyle intervention aimed at modest weight loss through diet and exercise, treatment with generic metformin, or a placebo control. DPP findings published in 2002 indicated that, relative to placebo, lifestyle intervention and metformin reduced the rate of conversion to diabetes by 58% and 31%, respectively, over 3 years.1
Metformin worked well in younger women with history of gestational diabetes. Exercise and life style modifications worked well in people ( both genders) above 60 years of age.
Most DPP participants (88%) enrolled in the DPPOS ( 10 year study) , in which continued follow-up demonstrated that the 10-year risk reduction for type 2 diabetes was 31% for lifestyle intervention and 18% for metformin.2
We need to wait and see in India for the effectiveness of life style modifications in the rural and urban populations in preventing IGT conversion to diabetes mellitus, this can avert major risks associated with the potential epidemic of diabetes in the coming years.
